![From QSR to QMSR: Meeting FDA’s New Requirements From QSR to QMSR: Meeting FDA’s New Requirements](https://www.fdanews.com/ext/resources/Book-Covers-NEW/From-QSR-to-QMSR-500.png?height=200&t=1714569011&width=200)
Home » Pharma Blog Watch
Pharma Blog Watch
October 17, 2006
New
Diabetes Drug Approved (Pharma's Cutting Edge)
In his entry, blogger Fred Cohen discusses the FDA's approval of Merck's diabetes
drug Januvia. "I'm already convinced that it is effective in relatively
early diabetes and has the exciting potential to slow the progressive beta cell
failure that is a hallmark of the disease," he writes.
"As far as safety, you'll recall that DPP-IV is a coactivator of T cells and is involved in metabolism of a number of peptides, so there is a theoretical safety issue with inhibiting it with a drug like Januvia," he continues. "That said, there's a very large potential patient base for this product in monotherapy and combination therapy, and I expect its uptake to be robust, better than the uptake of Avandia when it was first launched."
KEYWORDS Drug Pipeline Alert
Upcoming Events
-
21Oct